Bagsværd, Denmark, 1 October 2018 – Novo Nordisk today announced plans to make the durable, connected insulin pens NovoPen® 6 and NovoPen Echo® Plus commercially available across key markets commencing in early 2019. In parallel, to support the future integration of its connected pens with broader digital health solutions, Novo Nordisk has signed new partnership agreements with leading diabetes technology companies that share Novo Nordisk’s vision to improve the lives of people with diabetes: Dexcom, Glooko and Roche.

The partnerships aim to advance the solutions available for people living with diabetes and their healthcare professionals. Building upon its existing work with IBM Watson Health and Glooko, Novo Nordisk aims to seamlessly integrate insulin dosing data from connected pen devices with its partners’ open ecosystems and diabetes management solutions, such as data from continuous glucose monitoring (CGM) systems and blood glucose meters (BGM).

“Our non-exclusive partnership strategy allows us to integrate with the various digital platforms that people are already using to help manage their diabetes,” said Camilla Sylvest, executive vice president of Commercial Strategy & Corporate Affairs at Novo Nordisk. “We firmly believe that this will help more people realise the full benefit of our innovative medicines and begin to ease the mental burden of diabetes treatment for those individuals.”

The launch of Novo Nordisk’s first connected insulin pens, NovoPen® 6 and NovoPen Echo® Plus, will commence in the first quarter of 2019 and roll out to over 50 countries in the coming years. NovoPen® 6 and NovoPen Echo® Plus will eventually be phased in to replace NovoPen® 5 and NovoPen Echo® in countries where those devices are currently available.

“After receiving caregiver feedback, we knew a global roll-out was the right thing to do,” said Camilla Sylvest, referring to a 2017-18 Swedish pilot in collaboration with Glooko. “During the pilot, healthcare providers noted that patient dialogues improved without having to invest additional time.”

Global Head of Roche Diabetes Care Marcel Gmuender added that, “synching Novo Nordisk insulin data with our digital diabetes management solutions like mySugr and Accu-Chek Smart Pix will allow us to enhance quality of care and help create more sustainable healthcare systems.”

Novo Nordisk will also integrate insulin dosing data with Dexcom CGM data in the coming years. “We believe that a fully connected ecosystem represents a significant opportunity to improve the lives of people on multiple daily injections,” said Steve Pacelli, executive vice president of Strategy & Corporate Development at Dexcom.

“We are pleased to extend our collaboration with Novo Nordisk,” said Russ Johannesson, CEO at Glooko. “We are excited about evolving our integrated solutions and look forward to helping more people manage their diabetes via the Glooko platform.”

Beyond launching connected durable devices, Novo Nordisk expects to deliver connectivity for its disposable, pre-filled injection pens later in 2019. In the longer term, Novo Nordisk aims to increase the availability of connected pens and offer solutions for personalised treatment guidance.

 

LONDON–(BUSINESS WIRE)–Jul. 12, 2018– Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that it has partnered with Glooko®, Inc. to connect Insulet’s Omnipod System user data with Glooko+diasend®, the most comprehensive diabetes data management system available, across Europe.

“Insulet and Glooko are dedicated to bringing innovation to diabetes management around the world. We are delighted to work together to provide Omnipod users across Europe the ability to remotely sync data from their Omnipod Systems using Glooko+diasend,” said DJ Cass, General Manager, Insulet Europe. “This combined platform makes their lives easier by allowing people with diabetes to review their blood glucose patterns on their smartphones and monitor the impact of their insulin regimen, diet and physical activity on their diabetes management.”

Insulet’s partnership with Glooko is further proof of its commitment to putting customers first, as it ensures Insulet can continue to be closer to the diabetes community and provide personalised support for Podders™ across Europe.

“Glooko has a long-standing relationship with Insulet and we are very excited to now expand our collaboration even further within the European markets,” said Anders Sonesson, General Manager Glooko Europe. “We are proud to support the Omnipod System with our universal data management solution and our seamless user experience will appeal to numerous health care providers and their patients throughout Europe, taking clinic workflow, remote patient monitoring and overall diabetes treatment plans to new heights.”

Glooko+diasend is currently used at approximately 7,000 provider sites by over 1.5 million users in 23 countries, and the system is offered in 15 languages.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives.

On July 1, 2018, Insulet assumed direct operations of its Omnipod Insulin Management System product line in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as Insulet does in the United States and Canada.

For more information, please visit: www.insulet.com and www.myomnipod.com.

About Glooko:

Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. With Glooko, one can easily upload data from more than 160 devices such as blood glucose meters, insulin pumps, CGMs and several fitness and activity trackers — providing timely and verified data and enabling PWDs and care teams to correlate it with diet, exercise, medication and other data. Glooko provides care teams with an easy office data upload solution and a population health app so they can support PWDs during and in-between office visits. Trusted by the world’s leaders in diabetes care, Glooko is used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet’s expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 22, 2018 in the section entitled “Risk Factors,” and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

© 2018 Insulet Corporation. Omnipod, the Omnipod logo and Podders are trademarks or registered trademarks of Insulet Corporation. All rights reserved. Glooko and diasend are trademarks of Glooko, Inc. and used with permission.

Source: Insulet Corporation

Insulet Corporation
Investor Relations and Corporate Communications Contact:
Deborah R. Gordon, +1 978-600-7717
Vice President, Investor Relations and Corporate Communications
[email protected]
or
Media Contact:
Dominic Hulton, +44 20 3941 5374
Vice President, Marketing, Europe
[email protected]

Insights to be shared this weekend at the 
78th Scientific Sessions of American Diabetes Association

Mountain View, Calif. and Gothenburg, Sweden –June 22, 2018, Glooko, the leader in diabetes data management, today announced participation in the 78th Annual American Diabetes Association (ADA) meeting taking place this weekend in Orlando, Fla. At the event, Glooko will demonstrate the new version 5.0 of its diabetes management mobile application and will share results from a recent human factors study on its Mobile Insulin Dosing System (MIDS) for long-acting insulin (LAI) titration, which was FDA cleared earlier this year.

With over 95% of glucose, insulin pump and exercise devices supported, the new Glooko Mobile App focuses on features that add context to glucose and insulin data. Version 5.0 makes tracking personal lifestyle events like exercise, food and medication easier and faster. The new release includes:

“Glooko’s universal platform for diabetes data management not only seamlessly captures data from most diabetes devices in the market, but now makes lifestyle tracking easier than ever before,” said Dave Conn, Chief Commercial Officer at Glooko. He continued, “Adding further insights like food, medication, insulin, exercise and notes about mood, feelings and behaviors provides relevant context to an individual’s glucose readings and helps people with diabetes and clinicians better augment self-care and the overall clinical care plan.”

In addition to demonstrating the new Glooko Mobile App and the recently released version of the Glooko Web App, Glooko will also be presenting a poster at the ADA conference on Saturday, June 23, from 11:30-12:30 pm. The poster covers the results from a recent human factors study on the MIDS application – proving that MIDS is simple, effective, and easy-to-use for people with type 2 diabetes of varying ages, LAI experience, and smartphone use without training or reading a user manual. Participants reported overwhelmingly positive feedback and no participant expressed frustration when completing tasks despite any lack of training or prior experience with digital diabetes tools.

To learn more visit us in booth #1137 on the exhibition floor or come see our poster in the General Poster Session, Category 12-C Clinical Therapeutics/New Technology- Insulins #1055-P.

About Glooko

Glooko provides insights that improve outcomes for people with diabetes (PWDs) and their care teams. Glooko syncs data from the world’s most popular diabetes devices and major fitness and activity trackers and supplies personalized, timely insights based on blood glucose, food, insulin, blood pressure, diet and weight data. Trusted by the world’s leaders in diabetes care, Glooko is used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com

Agreement with Glooko Provides Broad Access of Insulin Pump Therapy Optimization to Physicians, Patients and Payers

PETAH TIKVA, Israel, June 18, 2018 /PRNewswire/ — DreaMed Diabetes, developer of personalized diabetes management solutions, announced today that the U.S Food and Drug Administration (FDA) has granted a De Novo request for DreaMed Advisor Pro, an artificial intelligence (AI)-based diabetes treatment decision support software. Advisor Pro is indicated to assist healthcare providers in the management of people with type 1 diabetes who use insulin pumps and continuous glucose monitoring (CGM).

DreaMed Advisor Pro is a cloud-based digital solution generating insulin delivery recommendations by analyzing information from CGM, self-monitoring blood glucose (SMBG), and insulin pump data. Applying event-driven adaptive learning, Advisor Pro refines its understanding for each individual and sends recommendations to the healthcare provider on how to optimize a patient’s insulin pump settings for basal rate, carbohydrate ratio (CR) and correction factor (CF).

“This is an innovation that can improve people’s lives and the FDA decision confirms what we believe is an important step in making a more meaningful connection between the healthcare provider and their type 1 diabetes patients,” said DreaMed CEO Eran Atlas. “Type 1 diabetes, managed with greater attention, leads to improved patient quality of life and reduced payer health-related costs. Advisor Pro enables patients using CGM and an insulin pump to analyze data and recommend to their provider when a change in diabetes-care treatment is timely and needed.”

There are more than one million people in the United States with type 1 diabetes1. According to the T1D Exchange, the largest clinic registry of patients with type 1 diabetes in the U.S., about 50% of patients in the registry use insulin pumps2. This added digital health capability is a step toward making pump and CGM technology more valuable in diabetes management.

Two years ago, in anticipation of the FDA review, DreaMed and Glooko, the leader in diabetes data management, signed an agreement that enables Advisor Pro to be integrated into the Glooko diabetes data management platform.

“This is a significant achievement and practical example of how AI and digital health can improve patient care and enable care teams,” said Russ Johannesson, CEO of Glooko. “We congratulate DreaMed and look forward to working closely with them to demonstrate that Advisor Pro can play a central role in optimizing insulin therapy.”

“Today marks a milestone for people living with type 1 diabetes (T1D). The FDA clearance reinforces why Helmsley supports the development of technologies like DreaMed Advisor Pro that show promise for improving lives in the T1D community,” said David Panzirer, a Trustee of The Leona M. and Harry B. Helmsley Charitable Trust, which in 2016 awarded a $3.4M grant in support of Advisor Pro. “Managing T1D can be overwhelming both for people living with it, and for their clinicians. The DreaMed Advisor Pro harnesses the power of AI to optimize insulin regimens, and will undoubtedly lead to better outcomes for people living with T1D – a driving vision here at Helmsley.”

This is the second regulatory approval for Advisor Pro this year, having received the EU CE Mark in February 2018. In addition, DreaMed received CE Mark for its artificial pancreas technology in 2015, Glucositter, which was licensed by global health technology leader Medtronic Diabetes.

About DreaMed Diabetes
DreaMed spun out of Schneider Children’s Medical Center in 2014, following seven years developing its artificial pancreas technology. Since then, DreaMed Diabetes develops solutions and personalized decision support solutions for the optimization of insulin therapy for people with Type 1 and Type 2 diabetes. The Company’s first product, GlucoSitter was developed for closed-loop insulin therapy and was licensed to Medtronic Diabetes. The Company then developed Advisor, a portfolio of decision support solutions for patients and healthcare providers dedicated to transform dynamic, real-world patient data into actionable treatment insights with its unique, cloud-based cognitive technology. Investors in the company include Medtronic Diabetes, Norma Investments and OurCrowd. For more information, please visit http://www.dreamed-diabetes.com.

1. http://www.diabetes.org/diabetes-basics/statistics/
2. https://t1dexchange.org/pages/

New version features support for the Ambulatory Glucose Profile (AGP), new dashboards and reports

Mountain View, Calif. and Gothenburg, Sweden –June 11, 2018, Glooko, the leader in diabetes data management, today announced the delivery of a new version of the Glooko Web Application (Population Tracker) that includes streamlined navigation and a large array of diabetes analytics, charts and graphs. The release is the result of over a year of development and research to identify the most insightful analytics features within the diasend® and Glooko platforms for people with diabetes (PWDs) and clinicians. Glooko and diasend®, both diabetes data management companies with a global presence, merged in the fall of 2016, and the release represents a culmination of joint efforts.

The new web application version, which will now be rolled out in the U.S. and Canada and continue with the first European phase later this year, includes support for IDC’s Ambulatory Glucose Profile (AGP), an important standard with clinicians. The release also includes the following new features:

“We are truly excited to supply PWDs and clinicians with the most comprehensive set of reports and analytics on diabetes data available today,” said Sam Wyndbrant, Director of Product Management at Glooko. “We listened to our customers’ feedback and added new features that will allow users to further separate the data that really matters from background noise. Patients and clinicians can now efficiently gain actionable insights from their data better than ever before.”

To learn more about the new features, watch this video or join us for this webinar.

 

World’s first long-term CGM system to be integrated with world’s leading diabetes management platform

GERMANTOWN, MD, June 10, 2018– Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced a partnership with Glooko, Inc, the leading diabetes data management company. The partnership enables integration of the long-term Eversense® branded continuous glucose monitoring (CGM) systems with Glooko’s diabetes data management platform.

The integration of these solutions will allow Eversense CGM data to be synced into Glooko’s platform directly from the Senseonics cloud. Eversense users will be able to view historical glucose and related data both in Glooko’s Mobile and Web Apps and will continue to get real-time readings from their Eversense Mobile Application. Healthcare professionals may view their patients’ data in the Glooko Population Tracker in interactive reports alongside other data resident in Glooko.

“With this integration, users can consolidate their glucose data with insulin, meals, medication and exercise to help them see glycemic patterns more readily. Glooko allows our users to take full advantage of both companies’ platforms and the large amount of data from our Eversense® and Eversense® XL systems” said Dr. Tim Goodnow, President and CEO of Senseonics. “Partnering with an innovative platform like Glooko fits with our strategy of giving people the tools to use all of their health data to conveniently and confidently make actionable lifestyle decisions.”

For Glooko, the integration of the Eversense systems is the first long-term sensor that will be compatible with their intelligent digital health platform. Users of the Eversense systems will have the opportunity to see how their glucose levels change over the long term without having to estimate the impact of frequent sensor changeovers and warm-up periods.

“We are thrilled to add Senseonics’ breakthrough Eversense and Eversense XL CGM data to our platform so that people with diabetes and clinicians can access this valuable data in context in our reports online and via mobile,“ said Russ Johannesson, Glooko’s CEO.   He continued, “Our cloud integration with Senseonics gives users easy access to their glucose data from the sensor, enabling them to make decisions based on their glucose patterns.”

The Eversense system has been integrated with Diasend in the EU since 2017. The companies expect implementation of the Eversense/Glooko data integration to be by the end of the year. Learnings from this partnership will benefit both organizations as they expand into insulin titration and decision support tools.

This global agreement covers all markets where Glooko and the Eversense Systems are currently available.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ first generation continuous glucose monitoring (CGM) system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.

Poster to be presented at the 2018 American Association of Clinical Endocrinologists annual meeting

Mountain View, Calif. and Gothenburg, Sweden –May 16, 2018, Glooko, the leader in diabetes data management, today announced the results of its recent study which  examined diabetes healthcare professionals’ use of CGM data. The study asked 38 diabetes healthcare professionals (29 endocrinologists; nine diabetes educators) to assess CGM data from 10 people with type 1 diabetes within the Glooko platform. The diabetes healthcare professionals were asked to qualitatively rank each patient’s daily glycemic control from “best” to “worst” and indicate which CGM data features were relevant in the ranking process.

Glooko provides a full range of features that enables healthcare professionals to quickly upload and visually analyze CGM data to help create, alter, and optimize patient care plans.

The poster can be downloaded in the Glooko Resource Center.

The27th Annual Scientific and Clinical Congress will be held May 16-20, 2018 in Boston. In addition to the poster presentation on May 18 from 5-6:30 pm, Glooko will be showcasing its products in booth 1607 on the exhibition floor.

BRIDGEWATER, New Jersey, April 20, 2018 — Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, announced today it has entered into an agreement with Glooko, a leader in diabetes data management. With this agreement, Valeritas will provide future V-Go SIM (Simple Insulin Management) users with Glooko’s cloud-based mobile and web diabetes data management platform to help track and analyze their diabetes care plan. Users can also share their data with their providers.

“We are thrilled to be partnering with Glooko and excited to be able to offer Glooko’s market-leading, diabetes data management platform to our customers when we introduce our V-Go SIM technology throughout the U.S. in the first half of 2019,” said John Timberlake, President and Chief Executive Officer of Valeritas. “We believe the combination of our flagship product V-Go, combined with our Bluetooth® technology enabled V-Go SIM and Glooko’s diabetes data management platform will allow adult patients with diabetes and their healthcare providers to optimize each patient’s diabetes management and care plan.”

“We are excited to bring V-Go’s easy and convenient insulin delivery solution coupled with the V-Go SIM technology onto the Glooko platform,” said Russ Johannesson, Glooko CEO. “With this integration, people with diabetes using the V-Go SIM accessory will be able to better understand the impact of seamless insulin delivery on their glycemic control and their care teams will be able to better optimize their use of this accessory.”

V-Go SIM is a new, durable accessory that will snap onto Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, and is designed to provide one-way Bluetooth communication from the V-Go SIM to a patient’s smart device. The V-Go SIM’s onboard electronics will provide information regarding V-Go’s use and wirelessly transmit such data via a V-Go SIM application (app) on a mobile device. This app will have the functionality to store, display, and share recorded on-board insulin delivery data and the status of V-Go to the patient and his or her healthcare provider. By partnering with Glooko, the patient can use the Glooko application not only to upload and analyze insulin usage data, but to also upload blood glucose levels and daily patient carbohydrate, food, and medication intake.  Combining this patient diabetes management data within the Glooko platform will give V-Go SIM users and their healthcare providers a more robust view of how each patient is managing his or her diabetes and will enable better informed regimen and behavior modifications.

The V-Go SIM is investigational and not expected to be available for full commercial use in the U.S. until the first half of 2019.  Valeritas and Glooko will be working collaboratively to ensure a seamless experience for V-Go SIM users and healthcare providers using the new platform when it becomes available.

 
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

More information is available at www.valeritas.com and our Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US.

About Glooko
Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. Glooko’s self-management mobile app automatically uploads data from devices including blood glucose meters, insulin pumps, CGMs and several fitness and activity trackers — providing timely and verified data and enabling PWDs and care teams to correlate it with diet, exercise, medication and other data. Glooko provides care teams with an easy office data upload solution and a population health app so they can support PWDs during and in-between office visits. Trusted by the world’s leaders in diabetes care, Glooko is used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages.  Learn more by visiting www.glooko.com

©2018 Glooko, Inc. Glooko and Diasend are trademarks of Glooko, Inc. All rights reserved.

Forward-Looking Statements
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.  Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.

Investor Contacts:

Lynn Pieper Lewis or Greg Chodaczek

Gilmartin Group

610-368-6505

[email protected]

Media Contact:

Kevin Knight

Knight Marketing Communications, Ltd.

(206) 451-4823

[email protected]

Growth and international expansion drive new addition to leadership team

Mountain View, California and Gothenburg, Sweden –April 10, 2018, Glooko, the leader in diabetes data management, today announced the appointment of Russ Johannesson as its new CEO. Outgoing CEO, Rick Altinger, will remain with Glooko as the Executive Vice President of Corporate Development.

Russ joins Glooko with over 25 years of healthcare and technology experience, and will lead Glooko’s continued growth and global expansion. Russ recently served as the Chief Operating Officer of Sharecare, where he helped drive overall corporate strategy and growth. Prior to his role at Sharecare, he served as the Chief Client Officer of OptumHealth where he was responsible for all sales, marketing, client management, support, implementation and growth operations for the over $8.1B business.

“Digital health solutions have proven impact for people with chronic diseases like diabetes and Glooko is driving real results among the patients and providers who use it,” said Russ Johannesson, newly appointed CEO of Glooko. “I am thrilled to be a part of a company with such a strong team, mission and product,” he continued.

Rick Altinger stated, “I look forward to getting back into a more hands on role and  working with Russ and the board to continue driving Glooko to its full potential.”

Russ joins Glooko to build on recent patient, provider and payer growth with both economic and clinical outcomes. Glooko continues to invest in its team with an emphasis on commercial growth and infrastructure.

“We are excited to welcome Russ to Glooko as he brings a wealth of expertise in scaling disease management solutions that meet the needs of patients, providers and payers,” said Board Member Wende Hutton of Canaan Partners. “On behalf of the entire board, we thank Rick for his commitment to Glooko over the last five years. Under his leadership, Glooko has established a strong clinical and patient footprint and has broadly provided real-world, data-driven insights about diabetes to the market.”

Russ’ appointment as CEO follows a series of exciting announcements for Glooko. In February, Glooko announced FDA clearance of its first clinical therapeutics application built on the Glooko platform, the Mobile Insulin Dosing System (MIDS). In 2017, Glooko increased its global provider base by over 2,000 offices and now boasts over 1.5M patients and over 7,000 providers on the platform.

About Glooko

Glooko provides insights that improve diabetes to people with diabetes (PWDs) and their care teams. Glooko syncs data from the world’s most popular diabetes devices and major fitness and activity trackers and supplies personalized, timely patient data such as blood glucose, food, insulin, blood pressure, diet and weight data.  Trusted by the world’s leaders in diabetes care, we are used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages.  Learn more by visiting www.glooko.com

©2018 Glooko, Inc. Glooko and Diasend are trademarks of Glooko, Inc. All rights reserved. PRM 0476 Rev A

Sharp Rees-Stealy Medical Group increases diabetes patient engagement with Glooko

Mountain View, California and Gothenburg, Sweden –March 14, 2018, Glooko, the leader in diabetes data management, today announced the results of its pilot program with Sharp Rees-Stealy Medical Group that aimed to optimize data-driven decisions for type 2 diabetes patients with high A1c levels. The six-month program revealed strong improvements in average blood glucose levels, patient adherence and engagement.

Spanning from April to October 2016, the Sharp Rees-Stealy care teams worked with 50 patients tracking patient engagement and a group of diabetes measures called diabetes Advanced Perfect Care (APC) which includes A1c, LDL, microalbumin (MALB) or Neph Screen and blood pressure before, during and after the pilot. At the start of the pilot, patients recorded an average BG of 160 mg/dL and by the end, patients improved their average BG by ~15 mg/dL (~10 percent). Additionally, patients doubled their daily BG testing frequency from less than one time per day to an average of 1.8 times per day.

“We’re excited to see compelling evidence from this program,” said Rick Altinger, CEO of Glooko. “One of the biggest challenges in diabetes care is leveraging the untapped data stored in disparate diabetes devices. A key aspect of this program was allowing patients to sync their data from their existing meters and receive actionable insights, mitigating hypo/hyper-glycemic events. We’re eager to continue this program to determine the impact Glooko can have on a larger patient population.”

Sharp Rees-Stealy assessed several different solutions that monitored patients’ glucose data remotely and ultimately selected Glooko because of its broad diabetes device support, easy-to-use mobile app, and collaborative approach. Due to the positive patient engagement and clinical outcomes results, Sharp Rees-Stealy is expanding to a second phase with Glooko, which will draw insights from the first phase and broaden the group of patients.

“Due to its intuitive and highly functional interface, Glooko’s tools appeal to a large portion of our patient population,” said Janet Appel, Director of Informatics and Population Health at Sharp Rees-Stealy. “When patients use Glooko, they feel empowered and it inspires them to better manage their condition; it makes them feel like they’re in control. The results and product are just a couple of reasons why we decided to move forward with a larger patient population.”

For more information & insights, download the full case study report here.                         

About Sharp Rees-Stealy Medical Group                               
As San Diego County’s first multispecialty medical group, Sharp Rees-Stealy offers high quality, affordable, coordinated primary and specialty care at 22 locations across San Diego. Founded in 1923, Sharp Rees-Stealy has more than 550 physicians and 2,800 staff members who represent virtually every field of medicine and are dedicated to delivering the extraordinary level of caring called The Sharp Experience, which combines clinical excellence, advanced technology and patient- and family-centered care.

Sharp Rees-Stealy is part of Sharp HealthCare, San Diego’s most comprehensive health care delivery system. To learn more visit www.sharp.com/srs or call 1-800-82-SHARP (1-800-827-4277) to choose a doctor who’s right for you.

About Glooko
Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. Our self-management mobile app automatically uploads data from devices including blood glucose meters, insulin pumps, CGMs and several fitness and activity trackers – providing timely and verified data and enabling PWDs and care teams to correlate it with diet, exercise, medication and other data. We provide care teams with an easy office data upload solution and a population health app so they can support PWDs during and in-between office visits. Trusted by the world’s leaders in diabetes care, we are used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages.  Learn more by visiting www.glooko.com

 

©2018 Glooko, Inc. Glooko and Diasend are trademarks of Glooko, Inc. All rights reserved. PRM 0468 Rev A